Replimune Deferred Long Term Liab vs Net Working Capital Analysis

REPL Stock

USD 5.10 0.09 1.80%

Replimune financial indicator trend analysis is much more than just breaking down Replimune Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Replimune Group is a good investment. Please check the relationship between Replimune Deferred Long Term Liab and its Net Working Capital accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

Deferred Long Term Liab vs Net Working Capital

Deferred Long Term Liab vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Replimune Group Deferred Long Term Liab account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Replimune's Deferred Long Term Liab and Net Working Capital is -0.35. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Replimune Group, assuming nothing else is changed. The correlation between historical values of Replimune's Deferred Long Term Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Replimune Group are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Deferred Long Term Liab i.e., Replimune's Deferred Long Term Liab and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.35

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Working Capital

Most indicators from Replimune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Replimune Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

At this time, Replimune's Selling General Administrative is quite stable compared to the past year. Enterprise Value is expected to rise to about 527.2 M this year, although the value of Tax Provision will most likely fall to about 255.2 K.

	2023	2024 (projected)
Depreciation And Amortization	2.7M	1.4M
Interest Income	580.8K	935.8K

Depreciation And Amortization Interest Income

Replimune fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.12	0.83	0.99	-0.86	0.95	0.92	-0.6	-0.8	0.64	0.93	0.92	0.91	0.91	1.0	0.81	0.93	0.88	0.26	0.94	0.93	0.97	0.59	0.93	0.78	1.0
Other Current Liab	0.12		0.39	0.06	-0.12	0.07	-0.14	0.35	-0.4	0.32	-0.14	-0.13	0.0	0.02	0.15	0.32	0.18	0.27	0.55	0.13	0.32	0.25	0.58	-0.07	0.28	0.16
Total Current Liabilities	0.83	0.39		0.8	-0.72	0.89	0.76	-0.09	-0.99	0.59	0.64	0.76	0.79	0.78	0.83	0.86	0.79	0.87	0.43	0.93	0.89	0.89	0.72	0.8	0.66	0.83
Total Stockholder Equity	0.99	0.06	0.8		-0.86	0.95	0.92	-0.64	-0.76	0.65	0.95	0.92	0.92	0.91	0.99	0.78	0.91	0.85	0.16	0.94	0.91	0.95	0.5	0.93	0.75	0.99
Other Liab	-0.86	-0.12	-0.72	-0.86		-0.84	-0.89	0.41	0.66	-0.85	-0.73	-0.9	-0.97	-0.97	-0.84	-0.87	-0.97	-0.64	-0.16	-0.83	-0.89	-0.83	-0.47	-0.89	-0.95	-0.84
Net Tangible Assets	0.95	0.07	0.89	0.95	-0.84		0.91	-0.47	-0.87	0.61	0.88	0.91	0.91	0.9	0.94	0.85	0.9	0.86	0.2	0.99	0.92	0.93	0.53	0.92	0.73	0.94
Property Plant And Equipment Net	0.92	-0.14	0.76	0.92	-0.89	0.91		-0.49	-0.73	0.6	0.85	1.0	0.96	0.96	0.9	0.83	0.92	0.79	0.18	0.9	0.86	0.89	0.5	1.0	0.79	0.9
Net Debt	-0.6	0.35	-0.09	-0.64	0.41	-0.47	-0.49		0.06	-0.22	-0.81	-0.49	-0.43	-0.42	-0.61	-0.14	-0.45	-0.33	0.16	-0.4	-0.33	-0.44	0.01	-0.47	-0.33	-0.6
Retained Earnings	-0.8	-0.4	-0.99	-0.76	0.66	-0.87	-0.73	0.06		-0.49	-0.61	-0.73	-0.74	-0.73	-0.8	-0.85	-0.75	-0.89	-0.45	-0.91	-0.88	-0.88	-0.73	-0.77	-0.6	-0.8
Accounts Payable	0.64	0.32	0.59	0.65	-0.85	0.61	0.6	-0.22	-0.49		0.48	0.61	0.77	0.75	0.63	0.61	0.75	0.34	-0.02	0.6	0.7	0.6	0.26	0.6	0.79	0.63
Cash	0.93	-0.14	0.64	0.95	-0.73	0.88	0.85	-0.81	-0.61	0.48		0.85	0.8	0.79	0.93	0.61	0.79	0.74	0.12	0.85	0.75	0.83	0.39	0.85	0.63	0.93
Non Current Assets Total	0.92	-0.13	0.76	0.92	-0.9	0.91	1.0	-0.49	-0.73	0.61	0.85		0.97	0.96	0.9	0.83	0.92	0.79	0.18	0.9	0.87	0.89	0.5	1.0	0.8	0.9
Non Currrent Assets Other	0.91	0.0	0.79	0.92	-0.97	0.91	0.96	-0.43	-0.74	0.77	0.8	0.97		1.0	0.89	0.86	0.95	0.73	0.1	0.9	0.92	0.89	0.45	0.96	0.86	0.89
Other Assets	0.91	0.02	0.78	0.91	-0.97	0.9	0.96	-0.42	-0.73	0.75	0.79	0.96	1.0		0.89	0.88	0.96	0.75	0.12	0.89	0.93	0.9	0.47	0.96	0.87	0.89
Cash And Short Term Investments	1.0	0.15	0.83	0.99	-0.84	0.94	0.9	-0.61	-0.8	0.63	0.93	0.9	0.89	0.89		0.8	0.91	0.88	0.27	0.94	0.92	0.97	0.6	0.91	0.76	1.0
Net Receivables	0.81	0.32	0.86	0.78	-0.87	0.85	0.83	-0.14	-0.85	0.61	0.61	0.83	0.86	0.88	0.8		0.92	0.82	0.47	0.86	0.93	0.88	0.74	0.86	0.88	0.8
Common Stock Total Equity	0.93	0.18	0.79	0.91	-0.97	0.9	0.92	-0.45	-0.75	0.75	0.79	0.92	0.95	0.96	0.91	0.92		0.79	0.31	0.89	0.94	0.91	0.62	0.93	0.95	0.91
Common Stock Shares Outstanding	0.88	0.27	0.87	0.85	-0.64	0.86	0.79	-0.33	-0.89	0.34	0.74	0.79	0.73	0.75	0.88	0.82	0.79		0.48	0.88	0.88	0.95	0.76	0.83	0.6	0.88
Non Current Liabilities Total	0.26	0.55	0.43	0.16	-0.16	0.2	0.18	0.16	-0.45	-0.02	0.12	0.18	0.1	0.12	0.27	0.47	0.31	0.48		0.25	0.28	0.33	0.92	0.23	0.39	0.27
Capital Surpluse	0.94	0.13	0.93	0.94	-0.83	0.99	0.9	-0.4	-0.91	0.6	0.85	0.9	0.9	0.89	0.94	0.86	0.89	0.88	0.25		0.93	0.94	0.58	0.92	0.73	0.94
Other Current Assets	0.93	0.32	0.89	0.91	-0.89	0.92	0.86	-0.33	-0.88	0.7	0.75	0.87	0.92	0.93	0.92	0.93	0.94	0.88	0.28	0.93		0.97	0.64	0.9	0.83	0.92
Other Stockholder Equity	0.97	0.25	0.89	0.95	-0.83	0.93	0.89	-0.44	-0.88	0.6	0.83	0.89	0.89	0.9	0.97	0.88	0.91	0.95	0.33	0.94	0.97		0.67	0.92	0.76	0.97
Total Liab	0.59	0.58	0.72	0.5	-0.47	0.53	0.5	0.01	-0.73	0.26	0.39	0.5	0.45	0.47	0.6	0.74	0.62	0.76	0.92	0.58	0.64	0.67		0.55	0.62	0.6
Property Plant And Equipment Gross	0.93	-0.07	0.8	0.93	-0.89	0.92	1.0	-0.47	-0.77	0.6	0.85	1.0	0.96	0.96	0.91	0.86	0.93	0.83	0.23	0.92	0.9	0.92	0.55		0.8	0.92
Preferred Stock Total Equity	0.78	0.28	0.66	0.75	-0.95	0.73	0.79	-0.33	-0.6	0.79	0.63	0.8	0.86	0.87	0.76	0.88	0.95	0.6	0.39	0.73	0.83	0.76	0.62	0.8		0.77
Total Current Assets	1.0	0.16	0.83	0.99	-0.84	0.94	0.9	-0.6	-0.8	0.63	0.93	0.9	0.89	0.89	1.0	0.8	0.91	0.88	0.27	0.94	0.92	0.97	0.6	0.92	0.77

Click cells to compare fundamentals

Replimune Account Relationship Matchups

Replimune fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	234.1M	543.1M	461.2M	646.6M	487.7M	359.6M
Other Current Liab	303K	514K	1.3M	3.0M	3.3M	2.2M
Total Current Liabilities	11.9M	14.5M	20.8M	33.8M	40.4M	42.5M
Total Stockholder Equity	183.7M	498.7M	411.2M	555.3M	374.5M	291.7M
Net Tangible Assets	137.9M	183.7M	498.7M	411.2M	472.9M	496.6M
Property Plant And Equipment Net	58.2M	57.7M	55.6M	52.4M	52.4M	39.7M
Net Debt	(17.7M)	(149.2M)	(73.1M)	(85.8M)	1.4M	1.5M
Retained Earnings	(112.3M)	(193.2M)	(311.2M)	(485.5M)	(701.3M)	(666.2M)
Accounts Payable	3.4M	2.4M	3.7M	5.4M	2.6M	3.7M
Cash	59.5M	182.5M	105.9M	146.6M	74.5M	87.0M
Non Current Assets Total	59.8M	59.4M	57.2M	54.0M	54.1M	41.1M
Cash And Short Term Investments	168.6M	476.3M	395.7M	583.4M	420.7M	311.0M
Net Receivables	3.0M	3.0M	3.1M	2.9M	4.9M	3.2M
Common Stock Total Equity	24K	32K	37K	47K	54.1K	31.9K
Common Stock Shares Outstanding	34.3M	46.2M	52.2M	58.2M	66.6M	47.1M
Short Term Investments	109.1M	293.8M	289.7M	436.8M	346.2M	223.9M
Liabilities And Stockholders Equity	234.1M	543.1M	461.2M	646.6M	487.7M	359.6M
Non Current Liabilities Total	38.5M	29.8M	29.2M	57.5M	72.8M	48.8M
Capital Surpluse	1.1M	198.6M	297.0M	692.2M	796.1M	835.9M
Other Current Assets	2.7M	4.5M	5.3M	6.3M	8.1M	4.4M
Other Stockholder Equity	297.0M	692.2M	723.4M	1.0B	1.1B	552.5M
Total Liab	50.4M	44.4M	50.0M	91.3M	113.2M	67.8M
Property Plant And Equipment Gross	58.2M	57.7M	60.4M	59.6M	62.3M	42.8M
Total Current Assets	174.3M	483.7M	404.0M	592.6M	433.7M	318.5M
Accumulated Other Comprehensive Income	(982K)	(394K)	(973K)	5.7M	4.9M	5.1M
Common Stock	32K	37K	47K	57K	61K	40.0K
Property Plant Equipment	12.2M	58.2M	7.4M	55.6M	63.9M	67.1M
Net Invested Capital	193.5M	498.7M	411.2M	583.9M	419.3M	362.1M
Net Working Capital	162.4M	469.2M	383.2M	558.8M	393.2M	339.0M
Short Long Term Debt Total	41.8M	33.3M	32.8M	60.8M	75.9M	46.0M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Replimune Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Replimune Group is a strong investment it is important to analyze Replimune's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Replimune's future performance. For an informed investment choice regarding Replimune Stock, refer to the following important reports:

How To Invest In Replimune

Details

Is Replimune Stock a good investment?

Details

What is Replimune's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.

You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Replimune Stock analysis

When running Replimune's price analysis, check to measure Replimune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Replimune is operating at the current time. Most of Replimune's value examination focuses on studying past and present price action to predict the probability of Replimune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Replimune's price. Additionally, you may evaluate how the addition of Replimune to your portfolios can decrease your overall portfolio volatility.

	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	CEOs Directory Screen CEOs from public companies around the world
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Replimune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.24)

Return On Assets

(0.26)

Return On Equity

(0.46)

The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Replimune Deferred Long Term Liab vs Net Working Capital Analysis

Deferred Long Term Liab vs Net Working Capital

Deferred Long Term Liab vs Net Working Capital Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Working Capital

Replimune fundamental ratios Correlations

Replimune Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Replimune fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Replimune Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Non Current Assets Total
Other Assets	+ 1.0	Non Currrent Assets Other

Retained Earnings	- 0.99	Total Current Liabilities
Common Stock Total Equity	- 0.97	Other Liab
Other Assets	- 0.97	Other Liab
Non Currrent Assets Other	- 0.97	Other Liab
Preferred Stock Total Equity	- 0.95	Other Liab
Capital Surpluse	- 0.91	Retained Earnings